Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Rating of "Buy" from Analysts

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has been assigned a consensus rating of "Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $50.00.

A number of equities research analysts have recently commented on the stock. KeyCorp upped their target price on shares of Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. StockNews.com upgraded shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th.

Simulations Plus Trading Down 0.2%

Shares of SLP stock traded down $0.08 on Monday, reaching $30.68. 22,746 shares of the stock were exchanged, compared to its average volume of 210,166. The business's 50 day moving average price is $28.96 and its 200 day moving average price is $30.24. The company has a market capitalization of $616.90 million, a price-to-earnings ratio of 76.88 and a beta of 1.10. Simulations Plus has a twelve month low of $23.01 and a twelve month high of $50.98.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The company had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. During the same quarter in the prior year, the firm posted $0.20 earnings per share. Simulations Plus's revenue for the quarter was up 22.5% on a year-over-year basis. Equities research analysts forecast that Simulations Plus will post 1.09 earnings per share for the current year.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the sale, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 19.40% of the company's stock.

Institutional Trading of Simulations Plus

Hedge funds have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in Simulations Plus during the fourth quarter worth approximately $719,000. Barclays PLC boosted its position in Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company's stock worth $911,000 after acquiring an additional 22,669 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock worth $1,517,000 after acquiring an additional 24,371 shares during the last quarter. Sei Investments Co. acquired a new stake in Simulations Plus during the fourth quarter worth approximately $330,000. Finally, Tributary Capital Management LLC boosted its holdings in shares of Simulations Plus by 21.7% in the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company's stock valued at $11,047,000 after purchasing an additional 70,526 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.